54 Les biomarqueurs moléculaires en oncologie
2. Trautmann K, Terdiman JP, French AJ, et al. (2006) Chromosomal instability in
l l
microsatellite-unstable and stable colon cancer. Clin Cancer Res 12: 6379-85
3. Kondo Y, Issa JP (2004) Epigenetic changes in colorectal cancer. Cancer Metastasis Rev
23: 29-39
4. Weisenberger DJ, Siegmund KD, Campan M, et al. (2006) CpG island methylator
phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF
mutation in colorectal cancer. Nat Genet 38: 787-93
5. Shen L, Toyota M, Kondo Y, et al. (2007) Integrated genetic and epigenetic analysis
l l
identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104: 18654-9
6. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and
colorectal cancer prognosis. J Clin Oncol 23: 609-18
7. Hutchins G, Southward K, Handley K, et al. (2011) Value of mismatch repair, KRAS, and
BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal
cancer. J Clin Oncol 29: 1261-70
8. Walther A, Houlston R, Tomlinson I (2008) Association between chromosomal instability
and prognosis in colorectal cancer: a meta-analysis. Gut 57: 941-50
9. Barault L, Charon-Barra C, Jooste V, et al. (2008) Hypermethylator phenotype in sporadic
colon cancer: study on a population-based series of 582 cases. Cancer Res 68: 8541-6
10. Roth AD, Tejpar S, Delorenzi M, et al. (2010) Prognostic role of KRAS and BRAF in
l l
stage II and III resected colon cancer: results of the translational study on the PETACC-3,
EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-74
11. Ogino S, Shima K, Meyerhardt JA, et al. (2012) Predictive and prognostic roles of BRAF
l l
mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin
Cancer Res 18: 890-900
12. Richman SD, Seymour MT, Chambers P, et al. (2009) KRAS and BRAF mutations in
advanced colorectal cancer are associated with poor prognosis but do not preclude benefit
from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27: 5931-7
13. Popovici V, Budinska E, Tejpar S, et al. (2012) Identification of a poor-prognosis BRAFl l
mutant-like population of patients with colon cancer. J Clin Oncol 30: 1288-95
14. O’Connell MJ, Lavery I, Yothers G, et al. (2010) Relationship between tumor gene
l l
expression and recurrence in four independent studies of patients with stage II/III colon
cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J
Clin Oncol 28: 3937-44
15. Salazar R, Roepman P, Capella G, et al. (2011) Gene expression signature to improve
l l
prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29: 17-24
16. Gray RG, Quirke P, Handley K, et al. (2011) Validation study of a quantitative multigene
l l
reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in
patients with stage II colon cancer. J Clin Oncol 29: 4611-9
17. O’Connell MJ, Lee M, Lopatin M, et al. (2012) Validation of the 12-Gene Colon Cancer
l l
Recurrence Score® Result in NSABP C-07 as a Predictor of Recurrence in Stage II and III
Colon Cancer Patients Treated with 5FU/LV (5FU) and 5FU/LV + Oxaliplatin (5FU+Ox).
ESMO, Vienne, 28 septembre-2 octobre
18. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan,
l l
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-42
19. Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab
plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:
337-45
20. Van Cutsem E, Peeters M, Siena S, et al. (2007) Open-label phase III trial of panitumumab
l l
plus best supportive care compared with best supportive care alone in patients with
chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-64
21. Ree AH, Dueland S, Folkvord S, et al. (2010) Vorinostat, a histone deacetylase inhibitor,
l l
combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic
Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11: 459-64
2. Trautmann K, Terdiman JP, French AJ, et al. (2006) Chromosomal instability in
l l
microsatellite-unstable and stable colon cancer. Clin Cancer Res 12: 6379-85
3. Kondo Y, Issa JP (2004) Epigenetic changes in colorectal cancer. Cancer Metastasis Rev
23: 29-39
4. Weisenberger DJ, Siegmund KD, Campan M, et al. (2006) CpG island methylator
phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF
mutation in colorectal cancer. Nat Genet 38: 787-93
5. Shen L, Toyota M, Kondo Y, et al. (2007) Integrated genetic and epigenetic analysis
l l
identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104: 18654-9
6. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and
colorectal cancer prognosis. J Clin Oncol 23: 609-18
7. Hutchins G, Southward K, Handley K, et al. (2011) Value of mismatch repair, KRAS, and
BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal
cancer. J Clin Oncol 29: 1261-70
8. Walther A, Houlston R, Tomlinson I (2008) Association between chromosomal instability
and prognosis in colorectal cancer: a meta-analysis. Gut 57: 941-50
9. Barault L, Charon-Barra C, Jooste V, et al. (2008) Hypermethylator phenotype in sporadic
colon cancer: study on a population-based series of 582 cases. Cancer Res 68: 8541-6
10. Roth AD, Tejpar S, Delorenzi M, et al. (2010) Prognostic role of KRAS and BRAF in
l l
stage II and III resected colon cancer: results of the translational study on the PETACC-3,
EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-74
11. Ogino S, Shima K, Meyerhardt JA, et al. (2012) Predictive and prognostic roles of BRAF
l l
mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin
Cancer Res 18: 890-900
12. Richman SD, Seymour MT, Chambers P, et al. (2009) KRAS and BRAF mutations in
advanced colorectal cancer are associated with poor prognosis but do not preclude benefit
from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27: 5931-7
13. Popovici V, Budinska E, Tejpar S, et al. (2012) Identification of a poor-prognosis BRAFl l
mutant-like population of patients with colon cancer. J Clin Oncol 30: 1288-95
14. O’Connell MJ, Lavery I, Yothers G, et al. (2010) Relationship between tumor gene
l l
expression and recurrence in four independent studies of patients with stage II/III colon
cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J
Clin Oncol 28: 3937-44
15. Salazar R, Roepman P, Capella G, et al. (2011) Gene expression signature to improve
l l
prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29: 17-24
16. Gray RG, Quirke P, Handley K, et al. (2011) Validation study of a quantitative multigene
l l
reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in
patients with stage II colon cancer. J Clin Oncol 29: 4611-9
17. O’Connell MJ, Lee M, Lopatin M, et al. (2012) Validation of the 12-Gene Colon Cancer
l l
Recurrence Score® Result in NSABP C-07 as a Predictor of Recurrence in Stage II and III
Colon Cancer Patients Treated with 5FU/LV (5FU) and 5FU/LV + Oxaliplatin (5FU+Ox).
ESMO, Vienne, 28 septembre-2 octobre
18. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan,
l l
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-42
19. Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab
plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:
337-45
20. Van Cutsem E, Peeters M, Siena S, et al. (2007) Open-label phase III trial of panitumumab
l l
plus best supportive care compared with best supportive care alone in patients with
chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-64
21. Ree AH, Dueland S, Folkvord S, et al. (2010) Vorinostat, a histone deacetylase inhibitor,
l l
combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic
Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11: 459-64